Mathes Company Inc. Sells 16,410 Shares of Johnson & Johnson (NYSE:JNJ)

Mathes Company Inc. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 82.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,585 shares of the company's stock after selling 16,410 shares during the period. Mathes Company Inc.'s holdings in Johnson & Johnson were worth $518,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. KLCM Advisors Inc. increased its holdings in shares of Johnson & Johnson by 2.0% in the fourth quarter. KLCM Advisors Inc. now owns 7,186 shares of the company's stock worth $1,039,000 after purchasing an additional 140 shares during the period. AlphaCentric Advisors LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth $2,629,000. Americana Partners LLC increased its holdings in shares of Johnson & Johnson by 141.4% in the fourth quarter. Americana Partners LLC now owns 185,084 shares of the company's stock worth $26,767,000 after purchasing an additional 108,399 shares during the period. Opus Capital Group LLC increased its holdings in shares of Johnson & Johnson by 79.2% in the fourth quarter. Opus Capital Group LLC now owns 3,939 shares of the company's stock worth $570,000 after purchasing an additional 1,741 shares during the period. Finally, Sierra Ocean LLC bought a new position in Johnson & Johnson in the fourth quarter valued at $295,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of the business's stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Stock Up 1.7 %

Shares of JNJ stock traded up $2.67 during trading hours on Friday, hitting $162.35. 12,540,171 shares of the company's stock traded hands, compared to its average volume of 9,073,381. The stock's fifty day simple moving average is $148.61 and its two-hundred day simple moving average is $155.89. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $168.85. The stock has a market cap of $390.87 billion, a price-to-earnings ratio of 24.41, a PEG ratio of 2.53 and a beta of 0.52. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm's quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the firm earned $2.29 earnings per share. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is currently 74.59%.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research analyst reports. Morgan Stanley reduced their target price on Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. Wells Fargo & Company reduced their target price on Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. Raymond James reduced their target price on Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada reissued an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday. Finally, Guggenheim increased their target price on Johnson & Johnson from $162.00 to $166.00 and gave the company a "neutral" rating in a research note on Monday, February 3rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.